- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02008435
Increasing the Effectiveness of the Diabetes Prevention Program
20 maart 2018 bijgewerkt door: Barbel Knauper, McGill University
Increasing the Effectiveness of the Diabetes Prevention Program Through If-then Plans and Mental Practice: A Parallel Randomized Trial
The Diabetes Prevention Program (DPP) is highly effective in promoting weight loss in overweight and obese individuals (e.g., 7% average loss of body weight), and thereby reducing the risk of developing weight-related health consequences.
One-on-one DPP sessions, however, are costly and the group-delivered DPP version, the Group Lifestyle Balance program (GLB), is less effective (4% average loss of body weight).
The aim of this two-arm parallel randomized controlled trial is to increase the effectiveness of the GLB by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
The study will provide evidence-based data on the effectiveness of an enhanced GLB intervention in promoting weight loss and in reducing weight-related risk factors for chronic health problems.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Please see brief summary.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
172
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1B1
- McGill University
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 75 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- men and women
- ages of 18 and 75
- overweight or obese (BMI 28-45 kg/m2)
- sedentary (< 200 min/week of moderate or vigorous exercise)
- waist circumference of >= 88cm for women and >= 102cm for men
Exclusion Criteria:
- diabetes (hemoglobin A1c < 7.0%).
- taking the medication metformin (used for treating pre-diabetes or diabetes)
- having been pregnant in the past 6 months or planning on becoming pregnant in the next 2 years
- currently undergoing treatment for cancer
- using medication that affects body weight (e.g., loop diuretics)
- being unable to participate in regular moderate physical activity
- having severe uncontrolled hypertension (> 190/100mm Hg)
- being unable to communicate in English or French
- being diagnosed with bulimia nervosa, currently active major depression, or other severe psychiatric disease (including dementia);
- suffering from a heart attack, stroke, or heart failure within the past 6 months
- experiencing excessive weight loss (more than 10 pounds or 4.54 kilograms) in the past 3 months
- currently participating in another weight loss program
- having had bariatric surgery in the past 2 years or plans on getting it in the near future
- planning on moving away from Montreal within the next year
- having another member of one's household enrolled in the program.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Enriched GLB
This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
|
Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
Andere namen:
|
|
Actieve vergelijker: Standard GLB
This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
|
This arm is the standard Group Lifestyle Balance program
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent body weight loss
Tijdsspanne: 3 months after beginning of the intervention
|
The primary outcome will be percent body weight loss from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months after beginning of the intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent body weight loss
Tijdsspanne: 12 months
|
Percent body weight loss 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
|
Percent body weight loss
Tijdsspanne: 24 months
|
Percent body weight loss 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
|
Personal weight loss goal
Tijdsspanne: 3 months
|
Reaching percent body weight loss goal (7% of body weight) from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months
|
|
Personal weight loss goal
Tijdsspanne: 12 months
|
Reaching percent body weight loss goal (7% of body weight) 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
|
Personal weight loss goal
Tijdsspanne: 24 months
|
Reaching percent body weight loss goal (7% of body weight) 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
|
Personal exercise goal
Tijdsspanne: 3 months
|
Reaching exercise goal (150 min/week) from baseline to 3 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
3 months
|
|
Personal exercise goal
Tijdsspanne: 12 months
|
Reaching exercise goal (150 min/week) 12 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
12 months
|
|
Personal exercise goal
Tijdsspanne: 24 months
|
Reaching exercise goal (150 min/week) 24 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
24 months
|
|
Waist circumference
Tijdsspanne: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Waist circumference
Tijdsspanne: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Waist circumference
Tijdsspanne: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Hemoglobin A1c levels
Tijdsspanne: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Hemoglobin A1c levels
Tijdsspanne: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Hemoglobin A1c levels
Tijdsspanne: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Blood pressure
Tijdsspanne: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Blood pressure
Tijdsspanne: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Blood pressure
Tijdsspanne: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Total cholesterol/HDL ratio
Tijdsspanne: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Total cholesterol/HDL ratio
Tijdsspanne: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Total cholesterol/HDL ratio
Tijdsspanne: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Physical activity duration
Tijdsspanne: 3 months
|
Total minutes per week.
|
3 months
|
|
Physical activity duration
Tijdsspanne: 12 months
|
Total minutes per week.
|
12 months
|
|
Physical activity duration
Tijdsspanne: 24 months
|
Total minutes per week.
|
24 months
|
|
Number of steps taken per week
Tijdsspanne: 3 months
|
Steps taken per week, recorded using a pedometer.
|
3 months
|
|
Number of steps taken per week
Tijdsspanne: 12 months
|
Steps taken per week, recorded using a pedometer.
|
12 months
|
|
Number of steps taken per week
Tijdsspanne: 24 months
|
Steps taken per week, recorded using a pedometer.
|
24 months
|
|
Exercise stress test (EST)
Tijdsspanne: 3 months
|
3 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Self-Report Index of Habit Strength
Tijdsspanne: 3 months
|
Self-monitoring and behaviors
|
3 months
|
|
Self-Report Index of Habit Strength
Tijdsspanne: 12 months
|
Self-monitoring and behaviors
|
12 months
|
|
Self-Report Index of Habit Strength
Tijdsspanne: 24 months
|
Self-monitoring and behaviors
|
24 months
|
|
Habit formation indices of weight tracking
Tijdsspanne: 3 months
|
Frequency of weight tracking.
|
3 months
|
|
Habit formation indices of weight tracking
Tijdsspanne: 12 months
|
Frequency of weight tracking.
|
12 months
|
|
Habit formation indices of weight tracking
Tijdsspanne: 24 months
|
Frequency of weight tracking.
|
24 months
|
|
Habit formation indices of physical activity tracking
Tijdsspanne: 3 months
|
Frequency of physical activity tracking.
|
3 months
|
|
Habit formation indices of physical activity tracking
Tijdsspanne: 12 months
|
Frequency of physical activity tracking.
|
12 months
|
|
Habit formation indices of physical activity tracking
Tijdsspanne: 24 months
|
Frequency of physical activity tracking.
|
24 months
|
|
Habit formation indices of fat grams and calorie tracking
Tijdsspanne: 3 months
|
Frequency of food tracking.
|
3 months
|
|
Habit formation indices of fat grams and calorie tracking
Tijdsspanne: 12 months
|
Frequency of food tracking.
|
12 months
|
|
Habit formation indices of fat grams and calorie tracking
Tijdsspanne: 24 months
|
Frequency of food tracking.
|
24 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Studie directeur: Ilka Lowensteyn, PhD, McGill University
- Studie directeur: Lawrence Joseph, PhD, McGill University
- Studie directeur: Aleksandra Luszczynska, PhD, University of Colorado, Denver
- Studie directeur: Steven Grover, MD, McGill University
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Knauper B, Shireen H, Carriere K, Frayn M, Ivanova E, Xu Z, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The effects of if-then plans on weight loss: results of the 24-month follow-up of the McGill CHIP Healthy Weight Program randomized controlled trial. Trials. 2020 Jan 7;21(1):40. doi: 10.1186/s13063-019-4014-z.
- Knauper B, Carriere K, Frayn M, Ivanova E, Xu Z, Ames-Bull A, Islam F, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The Effects of If-Then Plans on Weight Loss: Results of the McGill CHIP Healthy Weight Program Randomized Controlled Trial. Obesity (Silver Spring). 2018 Aug;26(8):1285-1295. doi: 10.1002/oby.22226. Epub 2018 Jun 28.
- Knauper B, Ivanova E, Xu Z, Chamandy M, Lowensteyn I, Joseph L, Luszczynska A, Grover S. Increasing the effectiveness of the Diabetes Prevention Program through if-then plans: study protocol for the randomized controlled trial of the McGill CHIP Healthy Weight Program. BMC Public Health. 2014 May 18;14:470. doi: 10.1186/1471-2458-14-470.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 april 2013
Primaire voltooiing (Werkelijk)
1 december 2017
Studie voltooiing (Werkelijk)
1 december 2017
Studieregistratiedata
Eerst ingediend
6 december 2013
Eerst ingediend dat voldeed aan de QC-criteria
6 december 2013
Eerst geplaatst (Schatting)
11 december 2013
Updates van studierecords
Laatste update geplaatst (Werkelijk)
21 maart 2018
Laatste update ingediend die voldeed aan QC-criteria
20 maart 2018
Laatst geverifieerd
1 maart 2018
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MOP-123242
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Enriched GLB
-
University of PittsburghUnited States Department of DefenseVoltooidMetaboolsyndroom | PrediabetesVerenigde Staten
-
GluBio Therapeutics Inc.WervingAcute myeloïde leukemie | Myelodysplastische syndromenVerenigde Staten
-
Ohio State UniversityVoltooid
-
Hangzhou GluBio Pharmaceutical Co., Ltd.WervingNon-Hodgkin lymfoomChina
-
Hangzhou GluBio Pharmaceutical Co., Ltd.WervingAcute myeloïde leukemie | Myelodysplastische syndromen | Polycytemie Vera | Essentiële trombocytemie | Myelofibrose | Myeloïde maligniteitChina
-
Lovoria WilliamsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Actief, niet wervend
-
University of PittsburghVoltooidKwaliteit van het leven | Obesitas | Fysieke activiteit | Dieet Wijziging | Cardiovasculaire risicofactor | Mobiliteitsbeperking | Eetgedrag
-
Washington University School of MedicineBeëindigdObscuur gastro-intestinale bloedingVerenigde Staten
-
University of PittsburghRobert C. Atkins FoundationVoltooidSuikerziekteVerenigde Staten
-
Fisher and Paykel HealthcareVoltooid